Cargando…

Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.

High dose chemotherapy with autologous bone marrow transplantation (ABMT) has shown promise in several types of cancer. There is, however, a risk of transfusing contaminating tumour cells with the bone marrow cells, e.g. in patients with small cell lung carcinoma (SCLC). To eliminate SCLC cells from...

Descripción completa

Detalles Bibliográficos
Autores principales: Myklebust, A. T., Pharo, A., Fodstad, O.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968529/
https://www.ncbi.nlm.nih.gov/pubmed/8390285
_version_ 1782134760122875904
author Myklebust, A. T.
Pharo, A.
Fodstad, O.
author_facet Myklebust, A. T.
Pharo, A.
Fodstad, O.
author_sort Myklebust, A. T.
collection PubMed
description High dose chemotherapy with autologous bone marrow transplantation (ABMT) has shown promise in several types of cancer. There is, however, a risk of transfusing contaminating tumour cells with the bone marrow cells, e.g. in patients with small cell lung carcinoma (SCLC). To eliminate SCLC cells from normal human bone marrow, four monoclonal antibodies reactive with SCLC cells were used with immunomagnetic beads in model experiments. With two cycles of immunomagnetic elimination the individual antibodies removed 2.5-4.4 log of H-146 tumour cells from a single cell suspension, as assessed in a highly reproducible soft agar assay. Different combinations of two antibodies were only marginally more effective than the individual MAbs, whereas 5-6 log removal was obtained with a combination of all four antibodies. The method was equally effective when the tumour cells were mixed with bone marrow cells at a ratio of 1:10. The immunomagnetic procedure did not significantly affect the survival of normal progenitor cells, assessed in CFU-GM and CFU-GEMM assays. The results indicate that the procedure safely and effectively can be used to eliminate tumour cells from the bone marrow in conjunction with ABMT in patients with SCLC.
format Text
id pubmed-1968529
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19685292009-09-10 Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads. Myklebust, A. T. Pharo, A. Fodstad, O. Br J Cancer Research Article High dose chemotherapy with autologous bone marrow transplantation (ABMT) has shown promise in several types of cancer. There is, however, a risk of transfusing contaminating tumour cells with the bone marrow cells, e.g. in patients with small cell lung carcinoma (SCLC). To eliminate SCLC cells from normal human bone marrow, four monoclonal antibodies reactive with SCLC cells were used with immunomagnetic beads in model experiments. With two cycles of immunomagnetic elimination the individual antibodies removed 2.5-4.4 log of H-146 tumour cells from a single cell suspension, as assessed in a highly reproducible soft agar assay. Different combinations of two antibodies were only marginally more effective than the individual MAbs, whereas 5-6 log removal was obtained with a combination of all four antibodies. The method was equally effective when the tumour cells were mixed with bone marrow cells at a ratio of 1:10. The immunomagnetic procedure did not significantly affect the survival of normal progenitor cells, assessed in CFU-GM and CFU-GEMM assays. The results indicate that the procedure safely and effectively can be used to eliminate tumour cells from the bone marrow in conjunction with ABMT in patients with SCLC. Nature Publishing Group 1993-06 /pmc/articles/PMC1968529/ /pubmed/8390285 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Myklebust, A. T.
Pharo, A.
Fodstad, O.
Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.
title Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.
title_full Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.
title_fullStr Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.
title_full_unstemmed Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.
title_short Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.
title_sort effective removal of sclc cells from human bone marrow. use of four monoclonal antibodies and immunomagnetic beads.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968529/
https://www.ncbi.nlm.nih.gov/pubmed/8390285
work_keys_str_mv AT myklebustat effectiveremovalofsclccellsfromhumanbonemarrowuseoffourmonoclonalantibodiesandimmunomagneticbeads
AT pharoa effectiveremovalofsclccellsfromhumanbonemarrowuseoffourmonoclonalantibodiesandimmunomagneticbeads
AT fodstado effectiveremovalofsclccellsfromhumanbonemarrowuseoffourmonoclonalantibodiesandimmunomagneticbeads